Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.83 - $7.79
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.40M
Market Cap
$498.15M
Enterprise Value$450.71M
Total Cash (Recent Filing)$173.23M
Total Debt (Recent Filing)$33.39M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 05, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding88,325,134
10 Day Avg. Volume865,661
30 Day Avg. Volume1,395,292
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)4.05
P/FCF Ratio-7.33
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue7.14
Enterprise Value/Gross Profit55.95
Enterprise Value/Ebitda-5.29
Forecast
1Y Price Target
$7.07Price Target Upside55.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical Testing GrowthPSNL drove strong 59% quarter-over-quarter growth of its clinical tests with its partner Tempus, highlighting robust demand in this segment.
MRD Technology RecognitionGrowing optimism towards Personalis' opportunity in MRD and its solid pharma business supports a favorable outlook.
Pharma Contracts And DemandPSNL has had recent wins with pharma companies, signing two MRD contracts with biopharma companies expected to contribute $5 million each this year.
Bears Say
Biopharma And Enterprise Sales DeclineRevenue growth slowed to a decline as biopharma and enterprise sales more than offset growth in other areas.
Revenue Miss And Guidance ReductionPSNL reported total revenues of $17.2M, below the consensus estimate of $20.1M, and management lowered their 2025 revenue guidance.
Translational Pharma Services WeaknessPSNL specifically called out softness in the translational side of its pharma services business, including from Moderna, leading to lower guidance.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $2.83 and its highest was $7.79 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $498.15M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Nov 05, 2025 which is in 88 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Aug 05, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.01.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.28.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 88,325,134 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -21.986%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.07 (55.73% Upside)
$7.07 (55.73% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 523.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.65%
12-Months-Change
Fundamentals
Return on Equity
-60.26%
Trailing 12-Months
Asset Growth
39.45%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. (PSNL) is a leading genomics company that specializes in advanced genomic sequencing and analytics. The company operates primarily in the healthcare and biotechnology sectors, offering comprehensive solutions for genetic testing and analysis. Its core products and services include genomic testing for cancer and other genetic disorders, which are utilized by researchers, healthcare providers, and pharmaceutical companies for precision medicine and customized treatment plans.
PSNL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Despite strong growth in clinical adoption and partnership with Tempus, revenue and biopharma challenges, as well as a decline in gross margin, weigh on the outlook. The company's robust cash position and potential Medicare coverage provide positive future prospects.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$7.07
▲(55.73% Upside)
Technical Analysis
Ownership Overview
21.82% Insiders
3.38% Mutual Funds
45.08% Other Institutional Investors
16.42% Public Companies and
Individual Investors